Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Directorate Changes

18 May 2023 13:38

Directorate Changes

Directorate Changes

Seneca Growth Capital VCT Plc (the "Company")

18 May 2023

Appointment of Non-Executive Director and Appointment of Chair of the Audit Committee

Non-Executive Director

The Board of Seneca Growth Capital VCT Plc is delighted to announce that Mary Anne Cordeiro was today appointed to the Board as non-executive Director of the Company. Mary Anne has also joined the Company’s Audit Committee.

Mary Anne brings to the Board extensive knowledge of both the VCT and growth capital investment sectors, having been an advisor to or executive of innovative companies in the healthcare and technology sectors for over twenty years. Mary Anne has served as a non-executive Director of Albion Technology & General VCT Plc (“AATG”) from 2013 until 2023, following its merger with Albion Income & Growth VCT Plc where she had served as a non-executive Director from 2004. Having served nine years as non-executive Director, more recently as Senior Independent Director and Chair of the Remuneration Committee, Mary Anne is retiring from the AATG Board today. Mary Anne is also the Founder and Managing Director of Science to Business Limited which specialises in advising medical technology businesses on fundraising and commercialisation strategy. Prior to this Mary Anne had a fifteen-year career in international corporate finance as a M&A Investment Banker at Goldman Sachs International Limited, Vice President at Bankers Trust Company and Managing Director of Paribas’ Financial Institutions Group. Mary Anne holds a MA (Hons) in Chemistry from the University of Oxford and is a member of the University of Oxford’s Department of Chemistry Development Board.

Mary Anne will stand for election at the Annual General Meeting of the Company to be held in 2024. There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Mary Anne.

Chair of the Audit Committee

We are also pleased to announce that further to Richard Roth’s retirement from the Board , with effect from today’s Annual General Meeting, Alex Clarkson has been appointed as Chair of the Audit Committee. Alex qualified as a Chartered Accountant with PwC in 1998 and has served as an independent non-executive Director of the Company and been a member of the Audit Committee since 2019.

These appointments are in accordance with the Board’s succession plans as outlined in the Company’s 2022 Annual Report, which was published on 21 April 2023.

Board Composition

The Board maintains its composition of four non-executive Directors, comprising three independent non-executive Directors and one representative of the Company’s Investment Manager, Seneca Partners Limited.

The Company’s Board is mindful of the new Listing Rule requirements which came into force for accounting periods starting after 1 April 2022 which require the Company to either comply with, or explain its non-compliance with, new rules intended to improve the diversity of publicly listed Boards.

The new rules seek to achieve 40% Board representation from women, one senior board position to be held by a woman and one Director to be from an ethnic minority background. Whilst the Company does not yet fully comply with the requirements, the Board will continue to work to improve the Board’s composition, providing suitable candidates possess the key skills and experience required for the position. The Board will always appoint the best person for the job. It will not discriminate on the grounds of gender, race, ethnicity, religion, sexual orientation, age or physical ability. The Board also fully supports the aims of the Hampton Alexander Report, the Parker Review and the renewed focus and emphasis on diversity in the AIC Code of Corporate Governance.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Date   Source Headline
4th Jun 20261:34 pmRNSResults of Annual General Meeting voting
30th Apr 202612:12 pmRNSAnnual Report, Notice of AGM and new NAVs
20th Mar 20264:36 pmRNSUnaudited Net asset value (“NAV”) Update
28th Nov 202512:06 pmRNSShare Buy-back and Total Voting Rights
11th Nov 202512:11 pmRNSSecond Interim Dividend on B Shares
21st Oct 20252:40 pmRNSPDMR Shareholding
15th Oct 20254:26 pmRNSUpdated NAV & Ordinary Share Class Dividend
26th Sep 20251:50 pmRNSUnaudited Half-year Report for 6m to 30 June 2025
8th Aug 20254:05 pmRNSIssue of Equity and Total Voting Rights
2nd Jun 20253:15 pmRNSShare Buy-back and Total Voting Rights
22nd May 20251:20 pmRNSResult of AGM
12th May 20254:02 pmRNSInterim Capital Dividend on Ordinary Shares
7th May 20253:04 pmRNSIssue of Equity and Total Voting Rights
29th Apr 20253:58 pmRNSIssue of Supplementary Prospectus
23rd Apr 20254:15 pmRNSFinal results and Notice of AGM
4th Apr 20253:37 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20257:00 amRNSNet Asset Value(s)
19th Mar 20257:00 amRNSInterim Dividend on B Shares
11th Dec 20242:44 pmRNSDirector/PDMR Dealing
11th Dec 20242:39 pmRNSIssue of Equity and Total Voting Rights
15th Nov 20243:15 pmRNSShare Buy-back and Total Voting Rights
14th Nov 20243:32 pmRNSSecond Interim Dividend on B Shares
16th Oct 20247:00 amRNSNet Asset Value(s)
12th Sep 20242:11 pmRNSOffer for Subscription and Prospectus Publication
9th Aug 20243:20 pmGNWIssue of Equity and Total Voting Rights
6th Aug 202410:10 amGNWClosure of Offer for Subscription
25th Jul 20247:00 amGNWHalf-year Report
15th May 202412:16 pmGNWResult of AGM
1st May 20243:34 pmGNWIssue of Equity and Total Voting Rights
1st May 20247:00 amGNWB Share Net Asset Value
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.